Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab +/− Stereotactic Radiosurgery for Chordoma
Recruiting1 awardPhase 1
New York, New York
This trial is studying nivolumab with or without SRS to treat patients with chordoma. Nivolumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. SRS is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service